Back to Search Start Over

Novartis secures rights to Mesoblasts remestemcel-L for ARDS

Source :
Legal Monitor Worldwide. November 21, 2020
Publication Year :
2020

Abstract

Swiss pharma Novartis has inked an exclusive licence and collaboration agreement with Mesoblast to develop remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS. Currently, remestemcel-L is being studied [...]

Subjects

Subjects :
Novartis AG -- Licensing agreements
Mortality -- United Kingdom -- Switzerland
Pharmaceutical industry -- Licensing agreements
Adult respiratory distress syndrome
COVID-19
Company licensing agreement
Business, international
Law

Details

Language :
English
Database :
Gale General OneFile
Journal :
Legal Monitor Worldwide
Publication Type :
News
Accession number :
edsgcl.642392496

Tools

Authors Abstract Subjects Details